Managers / Q1 2026
NEXTBio Capital Management LP
CIK 0002038158 · 500 W 2ND STREET, SUITE 1900, AUSTIN, TX, 78701 · 650-501-0882
Summary
Nextbio Capital Management LP reported $215M in U.S.-listed holdings across 24 positions for Q1 2026.
Its largest position, 430, represents 14.8% of the portfolio.
Compared with Q4 2025, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 81.8% · $176M
- ADR · 13.2% · $28M
- Other · 5.0% · $11M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SMMTSUMMIT THERAPEUTICS INC | NEW | +89.7K | 89.7K | +$2M | $2M |
| CMPSCOMPASS PATHWAYS PLC | ADDED | +1.27M | 2.02M | +$6M | $11M |
| RYTMRHYTHM PHARMACEUTICALS INC | ADDED | +58.5K | 126.1K | +$4M | $11M |
| GPCRSTRUCTURE THERAPEUTICS INC | ADDED | +38.8K | 133.2K | −$146,391 | $6M |
| COGTCOGENT BIOSCIENCES INC | ADDED | +35.4K | 131.2K | +$2M | $5M |
| ZBIOZENAS BIOPHARMA INC | ADDED | +104.8K | 426.7K | −$3M | $8M |
| CMPXCOMPASS THERAPEUTICS INC | TRIMMED | −265.8K | 848.2K | −$1M | $4M |
| IRONDISC MEDICINE INC | ADDED | +9.9K | 52.7K | −$30,240 | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
Filing History
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.